TECH
Bio-Techne Corporation (TECH) SWOT Analysis Analysis (2026)
Strengths
Liquidity is strong versus peers, with a 4.55 current ratio and 3.35 quick ratio, supporting operational resilience despite working-capital intensity.
Leverage is modest relative to peers, as 0.07 net debt to EBITDA and 0.14 debt-to-equity reduce balance-sheet pressure and preserve flexibility.
ROIC of 7.8% indicates improved capital discipline, but it remains only middling versus stronger peers and does not yet signal a durable efficiency edge.
Weaknesses
A 144.6-day cash conversion cycle is structurally weak versus peers, tying up capital and limiting reinvestment capacity in a competitive market.
Low ROIC versus higher-return peers suggests the business is not yet converting invested capital into superior economic returns.
The absence of disclosed margin metrics limits evidence of operating leverage, leaving profitability positioning harder to defend against more efficient peers.
Opportunities
If working capital is shortened, the long cash conversion cycle could release cash faster than peers and improve structural capital efficiency.
Low leverage creates room to fund selective growth or resilience initiatives more easily than more indebted peers, without immediate balance-sheet strain.
Improving returns on invested capital would narrow the gap to stronger peers and could materially strengthen long-term competitive positioning.
Threats
Peers with faster cash conversion and higher returns on capital can compound faster, widening the structural gap in reinvestment capacity.
If working-capital intensity persists, the company may remain less efficient than peers even when demand is stable, pressuring relative valuation and flexibility.
Limited margin disclosure raises the risk that underlying profitability is weaker than peers, which would constrain competitive durability over the next two to five years.
Overall Score
TECH’s structural positioning versus peers is mixed, with balance-sheet strength offset by weak working-capital efficiency and only middling capital returns.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Bio-Techne Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

